首页> 外文期刊>Transplant international : >Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection.
【24h】

Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection.

机译:细胞毒性T淋巴细胞和CD40在肾移植早期排斥反应的活检中的预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

After renal transplantation, different immunological and non-immunological factors lead to long-term allograft deterioration. Acute rejection episodes are one risk factor for chronic renal allograft dysfunction (CRAD). Following the current Banff classification the histological grade in acute rejection episodes is of limited prognostic value, therefore, additional morphological surrogate markers would be helpful. We investigated the biopsies of 91 patients with early acute rejection episodes for the immunohistochemical expression of key molecules (perforin, granzyme B, TIA-1, CD40) in the T cell-mediated rejection process. Staining results were correlated to long-term allograft outcome. Patients with greater than 2% of granzyme B or greater than 25% of CD40-positive cells in the interstitial infiltrate showed significantly shorter allograft survival. Patients with a CD40-positive vascular rejection or greater than 2% of granzyme B-positive cells in the interstitial infiltrate were significantly correlated with an earlier onset of CRAD. Our findings provide potential morphological surrogate markers in biopsies with early acute rejection episodes after renal transplantation. These could become part of combined clinical and histological algorithms, allowing patient-specific risk estimation and customized therapy options to be made.
机译:肾移植后,不同的免疫和非免疫因素导致同种异体移植长期恶化。急性排斥反应是慢性移植肾功能不全(CRAD)的危险因素之一。按照目前的班夫分类标准,急性排斥反应的组织学分级具有有限的预后价值,因此,其他形态学替代标志物将有所帮助。我们调查了91例具有早期急性排斥反应的患者的活检组织中T细胞介导的排斥反应过程中关键分子(穿孔素,粒酶B,TIA-1,CD40)的免疫组织化学表达。染色结果与长期同种异体移植结果相关。间质浸润中颗粒酶B大于2%或CD40阳性细胞大于25%的患者显示同种异体移植物的存活时间明显缩短。间质浸润中CD40阳性血管排斥反应或颗粒酶B阳性细胞大于2%的患者与CRAD的早期发作显着相关。我们的发现为肾移植术后早期急性排斥反应的活检提供了潜在的形态学替代指标。这些可以成为组合的临床和组织学算法的一部分,从而可以进行针对患者的风险评估和定制治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号